Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan Clinical Oncology Group Study JCOG0211

Author:

Yamaguchi Motoko1,Tobinai Kensei2,Oguchi Masahiko3,Ishizuka Naoki4,Kobayashi Yukio2,Isobe Yasushi5,Ishizawa Kenichi6,Maseki Nobuo7,Itoh Kuniaki8,Usui Noriko9,Wasada Izumi10,Kinoshita Tomohiro11,Hotta Tomomitsu12,Tsukasaki Kunihiro13,Oshimi Kazuo14

Affiliation:

1. Mie University Graduate School of Medicine, Tsu, Japan

2. National Cancer Center Hospital, Tokyo, Japan

3. Japanese Foundation for Cancer Research Cancer Institute Hospital, Tokyo, Japan

4. National Center of Global Health and Medicine, Tokyo, Japan

5. Juntendo University School of Medicine, Tokyo, Japan

6. Tohoku University Hospital, Sendai, Japan

7. Saitama Cancer Center, Ina, Japan

8. National Cancer Center Hospital East, Kashiwa, Japan

9. Jikei University School of Medicine, Tokyo, Japan

10. Tokai University, Isehara, Japan

11. Aichi Cancer Center Hospital, Nagoya, Japan

12. National Hospital Organization Nagoya Medical Center, Nagoya, Japan

13. Nagasaki University Graduate School of Medicine, Nagasaki, Japan

14. Eisai, Tokyo, Japan

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Reference6 articles.

1. ES Jaffe, NL Harris, H Stein , etal : World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 2001 Lyon, France IARC Press

2. SH Swerdlow, E Campo, NL Harris , etal : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 Lyon, France IARC

3. Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211

4. Angiocentric Lymphoma of the Head and Neck: Patterns of Systemic Failure After Radiation Treatment

5. Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3